TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Teva reported Q3 2026 revenues of $4.4B (down 2% YoY) driven by generic pressure offset by strong innovative brand growth. The company raised full-year 2026 revenue outlooks: AUSTEDO to $2.55-2.65B (from $2.45-2.60B), AJOVY to $930-960M (from $850-870M), UZEDY to $290-310M (from $270-290M). Three key innovative brands collectively grew 33% YoY to ~$1.1B. Non-GAAP gross margin expanded 345bps to 58.7%, the highest in a decade. Company also received FDA approval for WELTRUZA (olanzapine LAI for schizophrenia), acquired BXCL-501 from BioXcel, and refinanced ~$4.9B debt while achieving investment-grade credit rating.
Why this rating
Guidance raises and margin expansion are real but partially offset by generic revenue declines and acquisition IPR&D charges reducing near-term earnings. Portfolio transformation is genuine but execution risks remain.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.